Search clinical trials for: Restasis (cyclosporine ophthalmic emulsion) 0.05%

Total 506 results

Allergan

Completed

Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye

Dry Eye Syndromes

United States
SCAI Therapeutics

Completed

Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis

Dry Eye Syndromes

Korea, Republic of
Taejoon Pharmaceutical Co., Ltd.

Completed

Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients

Dry Eye | Dry Eye Syndromes

Korea, Republic of
Aurinia Pharmaceuticals Inc.

Completed

Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

Dry Eye

United States
Baylor College of Medicine
Allergan

Terminated

The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface (CsA)

Dry Eye

United States
Julian M. Mackay-Wiggan
Allergan

Completed

Restasis for Treatment of Brittle Nails

Brittle Nails

United States
Allergan

Completed

Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%

Dry Eye Disease

United States
Allergan

Completed

Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis® (EMPOWER)

Dry Eye Syndromes

United States
Allergan

Completed

Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium

Pterygium

Singapore, United States, Australia
Allergan

Completed

Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease

Keratoconjunctivitis Sicca

United States
Allergan

Completed

Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients

Dry Eye Syndromes

United States
Johns Hopkins University

Completed

Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis

Atopic Keratoconjunctivitis

United States
Boston Sight
Allergan

Completed

Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% on Application of PROSE Devices for Management of Patients With Ocular Surface Disease

Ocular Surface Disease

United States
M.D. Anderson Cancer Center
Allergan

Withdrawn

Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel

Epiphora
Bausch & Lomb Incorporated
Synteract, Inc.

Completed

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

Keratoconjunctivitis Sicca

United States
Taejoon Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes

Dry Eye Syndromes

Korea, Republic of
Meir Medical Center

Unknown

Corneal Tear Film Imaging of the Cornea Before and After Restasis Therapy

Dry Eye Syndrome | Tear Film Insufficiency
Mahidol University

Completed

Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction

Meibomian Gland Dysfunction

Thailand
University of North Carolina, Chapel Hill
Allergan

Completed

Topical Cyclosporine Suspension for the Treatment of Brittle Nails

Brittle Nail Syndrome

United States
Allergan

Completed

Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy (IMPACT)

Dry Eye Syndromes

United States
Boston Sight

Withdrawn

Novel Use of Restasis and PROSE Devices

Ocular Surface Disease

United States
Allergan

Completed

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Ocular Hypertension | Glaucoma

United States
Surface Pharmaceuticals, Inc.

Completed

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

Dry Eye Disease

United States
DH Bio Co., Ltd.
BTO Pharm. Co., Ltd.

Completed

Efficacy and Safety Study of Haporine-S for Treatment of Moderate to Severe Dry Eye Syndromes

Dry Eye Syndromes

Korea, Republic of
Farwaniya Hospital

Completed

Topical Cyclosporin A 0.05% Eye Drops for Management of Symptomatic Acquired Punctal Stenosis. A Prospective, Controlled Clinical Study.

Management of Punctal Stenosis

Kuwait
Mahidol University

Completed

Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye

Stevens-Johnson Syndrome

Thailand
Aerie Pharmaceuticals

Completed

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Huons Co., Ltd.

Completed

Efficacy and Safety of HE10 for Dry Eye Syndrome

Dry Eye Syndrome
Hanlim Pharm. Co., Ltd.

Completed

Study of Tisporin Eye Drops Group and Restasis Eye Drops Group After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease (HL_TSPR_302)

Dry Eye Syndromes

Korea, Republic of
Hanlim Pharm. Co., Ltd.

Completed

Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group (Cyclosporine)

Dry Eye Syndromes

Korea, Republic of
Massachusetts Eye and Ear Infirmary

Terminated

The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye

Dry Eye

United States
Skye Bioscience, Inc.

Completed

Phase 2, Placebo-Controlled, Study Assessing the Safety and Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Patients With Elevated Eye Pressure

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Allergan

Terminated

Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease

Dry Eye Syndromes

United States
Allergan

Completed

Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence

Eyelash Hypotrichosis

United States
Aerie Pharmaceuticals

Completed

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Ocular Hypertension | Open Angle Glaucoma

Japan
Allergan

Completed

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

Ocular Hypertension | Glaucoma, Open-Angle

United States
Taejoon Pharmaceutical Co., Ltd.

Recruiting

Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients

Dry Eye Syndrome

Korea, Republic of
Aerie Pharmaceuticals

Completed

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
University of Alabama at Birmingham

Completed

Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers

Contact Lens Wearers With Dry Eye Syndrome

United States
University of Missouri-Columbia

Terminated

Pilot Study of a Homeopathic Therapy in Combination With Cyclosporin (Restasis) in the Treatment of Dry Eye Disease

Dry Eye Syndromes

United States
Center for Ophthalmic and Vision Research, LLC
Sun Pharmaceutical Industries Limited

Completed

CEQUA for Sjogren's Syndrome Dry Eye

Dry Eye | Dry Eye Syndromes | Sjogren's Syndrome

United States
Chulalongkorn University
Allergan

Unknown

Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes

Dry Eye

Thailand
Aerie Pharmaceuticals

Completed

Study of AR-13324 in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Chengdu University of Traditional Chinese Medicine

Completed

AST Combined With 0.05% Cyclosporin Eye Drop Improve Corneal Nerve Density in Patients With SS Dry Eye (AST/SS)

Dry Eye | Sjogren's Syndrome | Ocular Surface Disease

China
Aerie Pharmaceuticals

Completed

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Aerie Pharmaceuticals

Completed

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Sun Pharmaceutical Industries Limited

Completed

Effect of Cequa™ in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Alcon Research

Completed

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients

Ocular Hypertension | Open-angle Glaucoma
Campus Bio-Medico University

Completed

Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery (CSA2020)

Ocular Inflammation | Ocular Surface Disease

Italy

3

Subscribe